Ulf Dahlstrom

List of Publications by Citations

119 papers	4,491 citations	36 h-index	65 g-index
128 ext. papers	6,015 ext. citations	7.4 avg, IF	5.57 L-index

#	Paper	IF	Citations
119	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, **2013**, 15, 808-17	12.3	462
118	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2013**, 15, 1173-84	12.3	388
117	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *European Journal of Heart Failure*, **2016**, 18, 613-25	12.3	316
116	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, **2010**, 12, 1076-84	12.3	258
115	Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. *European Heart Journal*, **2014**, 35, 1559-67	9.5	176
114	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. *JACC: Heart Failure*, **2017**, 5, 565-574	7.9	148
113	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. *European Journal of Heart Failure*, **2017**, 19, 1624-1634	12.3	113
112	Heart failure registry: a valuable tool for improving the management of patients with heart failure. *European Journal of Heart Failure*, **2010**, 12, 25-31	12.3	111
111	Association between use of □blockers and outcomes in patients with heart failure and preserved ejection fraction. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2008-18	27.4	106
110	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. *Circulation: Heart Failure*, **2017**, 10,	7.6	104
109	Prognostic Significance of Resting Heart Rate and Use of □Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. *Circulation: Heart Failure*, **2015**, 8, 871-9	7.6	91
108	Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. *European Journal of Heart Failure*, **2017**, 19, 1606-1614	12.3	86
107	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2018**, 20, 1326-1334	12.3	86
106	Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. *European Journal of Heart Failure*, **2016**, 18, 503-11	12.3	81
105	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. *Journal of the American Heart Association*, **2018**, 7,	6	79
104	Frequent non-cardiac comorbidities in patients with chronic heart failure. *European Journal of Heart Failure*, **2005**, 7, 309-16	12.3	71
103	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of □0. *Circulation: Heart Failure*, **2015**, 8, 862-70	7.6	64

102	Nurse-led heart failure clinics in Sweden. *European Journal of Heart Failure*, **2001**, 3, 139-44	12.3	63
101	Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. *European Heart Journal*, **2015**, 36, 2318-26	9.5	60
100	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. *European Journal of Heart Failure*, **2015**, 17, 1252-61	12.3	58
99	Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2017**, 19, 1270-1279	12.3	54
98	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. *JACC: Heart Failure*, **2019**, 7, 306-317	7.9	54
97	Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. *Journal of the American College of Cardiology*, **2016**, 68, 1404-1416	15.1	53
96	Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. *JACC: Heart Failure*, **2019**, 7, 505-515	7.9	50
95	Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. *European Journal of Heart Failure*, **2017**, 19, 1107-1116	12.3	47
94	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. *Journal of the American College of Cardiology*, **2017**, 69, 2606-2618	15.1	47
93	Patients with congestive heart failure and their conceptions of their sleep situation. *Journal of Advanced Nursing*, **2001**, 34, 520-9	3.1	47
92	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. *The Lancet Global Health*, **2020**, 8, e411-e422	13.6	46
91	Association of candesartan vs losartan with all-cause mortality in patients with heart failure. *JAMA - Journal of the American Medical Association*, **2011**, 305, 175-82	27.4	46
90	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. *JACC: Heart Failure*, **2017**, 5, 14-24	7.9	42
89	Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. *PLoS Medicine*, **2018**, 15, e1002540	11.6	42
88	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. *Circulation*, **2019**, 140, 1530-1539	16.7	41
87	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. *Europace*, **2015**, 17, 424-31	3.9	39
86	Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. *European Journal of Heart Failure*, **2015**, 17, 612-9	12.3	39
85	Prevalence and prognostic impact of kidney disease on heart failure patients. *Open Heart*, **2016**, 3, e000324	3	38

84	Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. *Clinical Research in Cardiology*, **2019**, 108, 1025-1033	6.1	36
83	Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2014**, 16, 409-18	12.3	33
82	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. *JACC: Heart Failure*, **2019**, 7, 65-76	7.9	32
81	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. *European Journal of Heart Failure*, **2015**, 17, 527-33	12.3	30
80	Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. *Circulation: Heart Failure*, **2015**, 8, 252-60	7.6	30
79	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. *Heart*, **2015**, 101, 1139-48	5.1	28
78	Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center?. *Journal of the American College of Cardiology*, **2014**, 63, 661-671	15.1	28
77	Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. *Circulation: Heart Failure*, **2013**, 6, 174-83	7.6	27
76	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2019**, 21, 471-479	12.3	26
75	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. *Circulation: Heart Failure*, **2016**, 9,	7.6	25
74	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. *Upsala Journal of Medical Sciences*, **2019**, 124, 65-69	2.8	25
73	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. *European Journal of Heart Failure*, **2020**, 22, 2160-2171	12.3	24
72	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. *JACC: Heart Failure*, **2018**, 6, 246-256	7.9	22
71	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. *European Journal of Heart Failure*, **2017**, 19, 366-376	12.3	21
70	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. *Diabetes and Vascular Disease Research*, **2018**, 15, 494-503	3.3	21
69	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. *JAMA Cardiology*, **2020**, 5, 401-410	16.2	20
68	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. *Journal of Cardiac Failure*, **2018**, 24, 365-374	3.3	19
67	Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure. *Open Heart*, **2017**, 4, e000568	3	18

66	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. *Heart*, **2018**, 104, 1093-1100	5.1	18
65	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. *International Journal of Cardiology*, **2020**, 298, 59-65	3.2	18
64	Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry. *Value in Health*, **2015**, 18, 439-48	3.3	16
63	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2020**, 22, 1390-1398	12.3	15
62	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. *European Journal of Heart Failure*, **2018**, 20, 474-480	12.3	15
61	Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2020**, 22, 103-112	12.3	15
60	Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. *European Journal of Heart Failure*, **2018**, 20, 769-777	12.3	14
59	Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure. *Circulation: Heart Failure*, **2017**, 10,	7.6	14
58	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2017**, 10,	7.6	13
57	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. *Clinical Research in Cardiology*, **2019**, 108, 1394-1405	6.1	13
56	Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial. *Acta Medica Scandinavica*, **1984**, 216, 199-207		13
55	A comprehensive assessment of the association between anemia, clinical covariates and outcomes in a population-wide heart failure registry. *International Journal of Cardiology*, **2016**, 211, 124-31	3.2	11
54	Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. *International Journal of Cardiology*, **2014**, 175, 55-61	3.2	11
53	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2021**, 23, 973-982	12.3	11
52	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. *Heart*, **2016**, 102, 1464-71	5.1	11
51	Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. *BMC Cardiovascular Disorders*, **2016**, 16, 39	2.3	10
50	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2021**, 23, 1012-1022	12.3	10
49	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. *International Journal of Cardiology*, **2020**, 313, 76-82	3.2	9

48	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. *International Journal of Cardiology*, **2018**, 254, 203-209	3.2	9
47	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. *JAMA Cardiology*, **2021**,	16.2	9
46	Clinical and research implications of serum versus plasma potassium measurements. *European Journal of Heart Failure*, **2019**, 21, 536-537	12.3	9
45	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. *International Journal of Cardiology*, **2019**, 287, 66-72	3.2	8
44	Responder to BNP-guided treatment in heart failure. The process of defining a responder. *Scandinavian Cardiovascular Journal*, **2015**, 49, 316-24	2	8
43	Association of diuretic treatment at hospital discharge in patients with heart failure with all-cause short- and long-term mortality: A propensity score-matched analysis from SwedeHF. *International Journal of Cardiology*, **2018**, 257, 118-124	3.2	8
42	Resource use and cost implications of implementing a heart failure program for patients with systolic heart failure in Swedish primary health care. *International Journal of Cardiology*, **2014**, 176, 731-8	3.2	8
41	Prognostic impact over time of ischaemic heart disease vs. non-ischaemic heart disease in heart failure. *ESC Heart Failure*, **2020**, 7, 264-273	3.7	8
40	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). *International Journal of Cardiology*, **2016**, 220, 750-8	3.2	8
39	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. *Heart*, **2021**, 107, 229-236	5.1	8
38	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2021**, 23, 1844-1854	12.3	8
37	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. *International Journal of Cardiology*, **2015**, 199, 415-23	3.2	7
36	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. *ESC Heart Failure*, **2020**, 7, 3633	3.7	6
35	Higher blood pressure in elderly hypertensive females, with increased arterial stiffness and blood pressure in females with the Fibrillin-1 2/3 genotype. *BMC Cardiovascular Disorders*, **2020**, 20, 180	2.3	5
34	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register. *Scandinavian Journal of Primary Health Care*, **2019**, 37, 434-443	2.7	5
33	Hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol. *Clinical Pharmacology and Therapeutics*, **1983**, 33, 701-9	6.1	5
32	Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. *Clinical Research in Cardiology*, **2021**, 110, 1051-1062	6.1	5
31	A registry-based algorithm to predict ejection fraction in patients with heart failure. *ESC Heart Failure*, **2020**, 7, 2388-2397	3.7	4

30	Proinsulin and IGFBP-1 predicts mortality in an elderly population. *International Journal of Cardiology*, **2014**, 174, 260-7	3.2	4
29	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.. *European Journal of Heart Failure*, **2022**,	12.3	4
28	Temporal trends in cause-specific readmissions and their risk factors in heart failure patients in Sweden. *International Journal of Cardiology*, **2020**, 306, 116-122	3.2	3
27	Established beta-adrenergic receptor blocking therapy and acute myocardial infarction. A clinical study of risks and benefits. *Acta Medica Scandinavica*, **1980**, 207, 167-71		3
26	Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure. *Journal of Patient-Reported Outcomes*, **2020**, 4, 50	2.6	3
25	Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction. *ESC Heart Failure*, **2020**, 7, 2894-2903	3.7	3
24	The impact of time to heart failure diagnosis on outcomes in patients tailored for heart failure treatment by use of natriuretic peptides. Results from the UPSTEP study. *International Journal of Cardiology*, **2017**, 236, 315-320	3.2	2
23	Young patients with heart failure: clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers. *European Journal of Heart Failure*, **2020**, 22, 1125-1132	12.3	2
22	Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. *European Journal of Heart Failure*, **2019**, 21, 1661-1662	12.3	2
21	Prenalterol in the treatment of congestive heart failure developing during beta-blocking therapy. A comparison with frusemide in patients with acute myocardial infarction. *Acta Medica Scandinavica*, **1982**, 212, 125-30		2
20	B-Type Natriuretic Peptide: Application in the Community. *Congestive Heart Failure*, **2008**, 14, 12-16		2
19	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry.. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**,	6.4	2
18	Prognosis and outcome determinants after heart failure diagnosis in patients who underwent aortic valvular intervention. *ESC Heart Failure*, **2021**, 8, 3237-3247	3.7	2
17	Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. *ESC Heart Failure*, **2019**, 6, 1167-1177	3.7	2
16	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. *American Heart Journal*, **2022**, 243, 11-14	4.9	2
15	Integration of B-type natriuretic Peptide in heart failure outpatient programs. *Congestive Heart Failure*, **2008**, 14, 9-11		1
14	Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.. *European Journal of Heart Failure*, **2022**,	12.3	1
13	Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.. *ESC Heart Failure*, **2022**,	3.7	1

12	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. *JACC: Heart Failure*, **2021**, 9, 349-359	7.9	1
11	Association Between Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. *Journal of Cardiac Failure*, **2021**, 27, 1165-1174	3.3	1
10	Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003-2015. *BMC Cardiovascular Disorders*, **2021**, 21, 307	2.3	1
9	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. *European Heart Journal Quality of Care & Clinical Outcomes*, **2020**, 6, 147-155	4.6	1
8	Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry. *ESC Heart Failure*, **2021**, 8, 85-94	3.7	1
7	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. *Europace*, **2021**,	3.9	1
6	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. *International Journal of Cardiology*, **2021**, 343, 63-72	3.2	1
5	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure.. *ESC Heart Failure*, **2022**,	3.7	1
4	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. *American Heart Journal*, **2020**, 222, 93-104	4.9	0
3	Integration of B-Type Natriuretic Peptide in Heart Failure Outpatient Programs. *Congestive Heart Failure*, **2008**, 14, 9-11		
2	1410 Depression and Patients with Chronic Heart Failure. A Review of the Literature. *European Journal of Cardiovascular Nursing*, **2005**, 4, 48-49	3.3	
1	Iron deficiency in heart failure. *International Journal of Cardiology*, **2020**, 299, 207	3.2	